Cidara Therapeutics to Report Second Quarter 2025 Financial Results and Host Quarterly Conference Call on August 7, 2025
Cidara Therapeutics (Nasdaq: CDTX), a biotechnology company specializing in drug-Fc conjugate (DFC) immunotherapies through its Cloudbreak® platform, has scheduled its second quarter 2025 financial results announcement for August 7, 2025.
The company will release its financial results and operational highlights after U.S. market close, followed by a conference call and webcast at 5:00 PM Eastern Time. Investors can access the call via U.S. toll-free (1-844-825-9789) or international (1-412-317-5180) numbers using Conference ID 10200740.
Cidara Therapeutics (Nasdaq: CDTX), un'azienda biotecnologica specializzata in immunoterapie coniugate a farmaci-Fc (DFC) tramite la sua piattaforma Cloudbreak®, ha programmato l'annuncio dei risultati finanziari del secondo trimestre 2025 per il 7 agosto 2025.
L'azienda pubblicherà i risultati finanziari e i principali aggiornamenti operativi dopo la chiusura del mercato statunitense, seguiti da una conference call e webcast alle 17:00 ora Eastern. Gli investitori potranno partecipare alla chiamata tramite i numeri gratuiti statunitensi (1-844-825-9789) o internazionali (1-412-317-5180) utilizzando l'ID conferenza 10200740.
Cidara Therapeutics (Nasdaq: CDTX), una empresa biotecnológica especializada en inmunoterapias conjugadas con fármaco-Fc (DFC) a través de su plataforma Cloudbreak®, ha programado el anuncio de sus resultados financieros del segundo trimestre de 2025 para el 7 de agosto de 2025.
La compañía publicará sus resultados financieros y aspectos operativos destacados después del cierre del mercado estadounidense, seguido de una llamada en conferencia y webcast a las 5:00 PM hora del Este. Los inversores pueden acceder a la llamada mediante números gratuitos en EE.UU. (1-844-825-9789) o internacionales (1-412-317-5180) usando el ID de conferencia 10200740.
Cidara Therapeutics (Nasdaq: CDTX)는 Cloudbreak® 플랫폼을 통해 약물-Fc 접합 면역치료제(DFC)를 전문으로 하는 생명공학 회사로, 2025년 2분기 재무 결과 발표를 2025년 8월 7일로 예정했습니다.
회사는 미국 증시 마감 후 재무 결과 및 주요 운영 현황을 발표하며, 이후 동부 표준시 오후 5시에 컨퍼런스 콜과 웹캐스트를 진행합니다. 투자자들은 미국 무료 전화(1-844-825-9789) 또는 국제 전화(1-412-317-5180)를 통해 회의 ID 10200740로 접속할 수 있습니다.
Cidara Therapeutics (Nasdaq : CDTX), une société de biotechnologie spécialisée dans les immunothérapies conjuguées à des médicaments-Fc (DFC) via sa plateforme Cloudbreak®, a programmé l'annonce de ses résultats financiers du deuxième trimestre 2025 pour le 7 août 2025.
La société publiera ses résultats financiers et les faits marquants opérationnels après la clôture du marché américain, suivis d'une conférence téléphonique et d'un webcast à 17h00 heure de l'Est. Les investisseurs peuvent accéder à l'appel via les numéros gratuits américains (1-844-825-9789) ou internationaux (1-412-317-5180) en utilisant l'ID de conférence 10200740.
Cidara Therapeutics (Nasdaq: CDTX), ein Biotechnologieunternehmen, das sich auf Wirkstoff-Fc-Konjugat (DFC) Immuntherapien über seine Cloudbreak®-Plattform spezialisiert hat, hat die Bekanntgabe der Finanzergebnisse für das zweite Quartal 2025 für den 7. August 2025 geplant.
Das Unternehmen wird seine Finanzergebnisse und operative Highlights nach Börsenschluss in den USA veröffentlichen, gefolgt von einer Telefonkonferenz und einem Webcast um 17:00 Uhr Eastern Time. Investoren können über die gebührenfreien US-Nummern (1-844-825-9789) oder internationale Nummern (1-412-317-5180) mit der Konferenz-ID 10200740 an der Telefonkonferenz teilnehmen.
- None.
- None.
SAN DIEGO, July 24, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced that it will report its second quarter 2025 financial results and operational highlights after the close of the U.S. financial markets on Thursday, August 7, 2025. The Company will host a conference call and webcast at 5:00 PM Eastern Time to discuss the results and provide an update on business operations.
Conference Call Dial-In & Webcast Information
| Date: | Thursday, August 7, 2025 |
| Time: | 5:00 PM Eastern Time |
| United States: | 1-844-825-9789 |
| International: | 1-412-317-5180 |
| Conference ID: | 10200740 |
| Webcast: | Link |
About Cidara Therapeutics
Cidara Therapeutics is using its proprietary Cloudbreak® platform to develop novel drug-Fc conjugates (DFCs) comprising targeted small molecules or peptides coupled to a proprietary human antibody fragment (Fc). Cidara’s lead DFC candidate, CD388, is a long-acting antiviral designed to achieve universal prevention of seasonal and pandemic influenza with a single dose by directly inhibiting viral proliferation. In June 2023, CD388 was granted Fast Track Designation by the U.S. Food and Drug Administration (FDA), and the Company announced positive top-line results from its Phase 2b NAVIGATE clinical trial in June 2025. Additional DFCs have been developed for oncology and in July 2024 Cidara received IND clearance for CBO421 which is intended to target CD73 in solid tumors. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.
INVESTOR CONTACT:
Brian Ritchie
LifeSci Advisors
(212) 915-2578
britchie@lifesciadvisors.com
MEDIA CONTACT:
Michael Fitzhugh
LifeSci Communications
mfitzhugh@lifescicomms.com
FAQ
When will Cidara Therapeutics (CDTX) report Q2 2025 earnings?
How can investors access Cidara Therapeutics' Q2 2025 earnings call?
What is Cidara Therapeutics' main technology platform?
What time is Cidara Therapeutics' Q2 2025 earnings call?
